Unraveling the Mechanisms Behind Resistance to Novel Cancer Therapies
“Predicting drug resistance is critical for precision oncology. This work reveals how cancers can evade dependencies on Wnt signalling and serves as a solid foundation for further development,”
Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore 169857, Singapore.
A team of scientists in Singapore has shed light on an important reason why some tumors may prove refractory to a class of emerging targeted drugs. Their research honed in on a cellular signaling network called Wnt that is aberrantly activated in numerous cancer types.
Wnt plays a role in stem cell maintenance and cell growth during the development of healthy tissues. However, genetic alterations can cause its deregulated signaling to drive cancer initiation and progression. In recent years, researchers identified certain mutations in genes such as RNF43 that result in dependency on continued Wnt pathway activity – a phenomenon known as oncogene “addiction.”
This addiction opened the door to developing drugs blocking Wnt signaling at upstream points. Early clinical trials evaluated inhibitors of a protein called PORCN, which is involved in Wnt ligand biogenesis. While some patients experienced durable responses, others saw their tumors continue growing, suggestive of intrinsic resistance.
Seeking clues, the scientists performed an in vivo screen finding a tumor suppressor gene called FBXW7 was disrupted in cell models resistant to PORCN inhibitors. FBXW7 helps eliminate particular cancer-driving proteins via the ubiquitin tagging system. Loss of this quality control function stabilized two culprit oncoproteins – Cyclin E and MYC – short-circuiting drug effects.
More remarkably, FBXW7 loss caused Wnt-addicted tumors to switch their dependency away from the β-catenin protein downstream of Wnt receptors. This suggested cancer cells develop alternate growth-promoting processes to evade targeted treatments, a worrying phenomenon known as oncogenic “pathway plasticity.”
Further experiments demonstrated multi-targeting compounds inhibiting cyclin-dependent kinase enzymes, which regulate the cell cycle and gene expression, effectively treat FBXW7-deficient models no longer responsive to upstream Wnt blockade. Assessing mutation profiles may help identify patients likely to benefit from such combination strategies.
Altogether, the findings provide new mechanistic insights into why some genetically defined cancers fail to respond long-term to rationally designed pathway inhibitors. Identifying and addressing resistance mechanisms like those uncovered will be pivotal to capitalizing on the precision afforded by new targeted therapies.
Reference(s)
- Zheng Zhong, David M. Virshup. Recurrent mutations in tumor suppressor FBXW7 bypass Wnt/β-catenin addiction in cancer. Science Advances, 2024; 10 (14) DOI: 10.1126/sciadv.adk1031
Click TAGS to see related articles :
BIOMARKERS | COLORECTAL CANCER | DIAGNOSTICS | ONCOLOGY | PANCREATIC CANCER
- Bacteria work together to thrive in difficult...on September, 2024 at 2:52 pm
In a new study, researchers have determined through both statistical analysis and in experiments that soil pH is a driver of microbial community composition -- but that the need to address toxicity released during nitrogen cycling ultimately shapes the final microbial community.
- Ignore antifungal resistance in fungal disease at...on September, 2024 at 4:33 am
Without immediate action, humanity will potentially face further escalation in resistance in fungal disease, a group of scientists from the around the world has warned. According to the scientists most fungal pathogens identified by the World Health Organization -- accounting for around 3.8 million […]
- Discovery could lead to longer-lasting EV...on September, 2024 at 6:24 pm
Researchers have discovered why lithium-ion batteries, which power most electronic devices, lose capacity overtime. The findings could enable the development of electric vehicles that go far longer without needing a charge.